Gilead 's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday.
The positive phase three trial data on lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention.
The company said 99.9% of participants who received lenacapavir did not acquire HIV, with two cases among 2,180 people.
Gilead in June also said lenacapavir was 100% effective at preventing HIV in another late-stage trial with cisgender women.
The trial results should lead to an FDA approval and launch in the market by 2025, Yee said.
Persons:
Gilead, Daniel O'Day, lenacapavir, Michael Yee, Yee
Organizations:
U.S . Food, Drug Administration, PrEP, Centers for Disease Control, Jefferies, CNBC, YouTube
Locations:
Gilead